مقالات پذیرفته شده در پنجمین کنگره بین المللی زیست پزشکی
Comparison of the effects of extended release tolterodine and solifenacin in treatment of overactive bladder symptoms
Comparison of the effects of extended release tolterodine and solifenacin in treatment of overactive bladder symptoms
maryam hajihashemy,1Tahere Eftekhar,2Maryam Deldar,3Mamak Shariat,4Zinat Ghanbari,5,*
2. Department of Obstetrics & Gynecology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran 3. Department of Obstetrics & Gynecology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran 4. Maternal, Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran 5. Department of Obstetrics & Gynecology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
Introduction: Overactive bladder (OAB) is defined as frequent and sudden urge to urinate that is difficult to control. Here we aimed to compare the effects of extended release tolterodine and solifenacin in treatment of OAB in Iranian population.
Methods: This was a prospective randomized clinical trial that was performed in 2021 in Imam Khomeini Hospital in Tehran on women with OAB. We collected demographic data of patients including age and history of patients. The 3-day frequency volume chart (FVC) and ICIQ-OAB questionnaire was then completed for each patient. The patients were randomly divided into two groups of A and B. An automated clinical trial service was used to assign patient number and provide the medication number indicated by the central randomization system. Group A received 4 mg of slow-release tolterodine and Group B received 5 mg solifenacin for 8 weeks. One month and two months after start of treatment, ICIQ-OAB questionnaire and the 3-day frequency volume chart (FVC) were obtained again.
Results: Totally, 51 patients in solifenacin group and 48 in tolterodine group completed the study. There was no significant difference between mean scores of ICIQ.OAB before treatment and one month after initiation of treatment between two groups (P> 0.05) but two months after treatment, the tolterodine group was significantly more than solifenacin group regarding mean scores of ICIQ.OAB (P <0.05). The mean score of ICIQ.OAB in both groups decreased over time (P <0.001). Two months after treatment, urgency in solifenacin group was significantly less than the tolterodine group (P <0.05). The average number of frequency, nocturia, urgency and the number of urinary leakage in both groups were significantly different in three times (P <0.05). The mean of all 4 variables in both groups decreased significantly over time (P <0.05).
Conclusion: solifenacin was superior to tolterodine in diminishing of ICIQ score. According to FVC, solifenacin was better to diminish urgency and more patient in solifenacin group and became dry after two months.